Success Metrics

Clinical Success Rate
57.1%

Based on 4 completed trials

Completion Rate
57%(4/7)
Active Trials
0(0%)
Results Posted
100%(4 trials)
Terminated
3(38%)

Phase Distribution

Ph phase_4
2
25%
Ph phase_2
4
50%
Ph phase_3
1
13%
Ph phase_1
1
13%

Phase Distribution

1

Early Stage

4

Mid Stage

3

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
4(50.0%)
Phase 3Large-scale testing
1(12.5%)
Phase 4Post-market surveillance
2(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

4 of 8 finished

Non-Completion Rate

50.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(4)
Terminated(4)

Detailed Status

Completed4
Terminated3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
57.1%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (12.5%)
Phase 24 (50.0%)
Phase 31 (12.5%)
Phase 42 (25.0%)

Trials by Status

terminated338%
completed450%
withdrawn113%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_2

Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma

NCT02218164
completedphase_2

Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas

NCT02343224
terminatedphase_1

Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion

NCT00791271
terminatedphase_4

Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients

NCT00803309
completedphase_3

PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327)

NCT00536263
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT02218164Phase 2

Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma

Completed
NCT02343224Phase 2

Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas

Completed
NCT00791271Phase 1

Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion

Terminated
NCT00803309Phase 4

Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients

Terminated
NCT00536263Phase 3

PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327)

Completed
NCT01727271Phase 4

A Study to Compare Efficacy and Safety of Tenofovir Used Alone or in Combination With Pegylated Interferon Alpha-2b in Participants With Chronic Hepatitis B and Elevated Alanine Aminotransferase (MK-4031-384)

Withdrawn
NCT00588146Phase 2

Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia

Terminated
NCT00310336Phase 2

Chronic Hepatitis C Non-Responder Study With AdoMet and Betaine

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8